ArticleInternational journal of nanomedicine2015
Design and activity of a cyclic mini-β-defensin analog: a novel antimicrobial tool.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 40 citations in OpenAlex.
- Boosting AMPs' Power: From Structural Engineering to Nanotechnology-Based Delivery.Molecules (Basel, Switzerland) · 2025Review
- Advances in the Role of Antimicrobial Peptides in the Management of Sexually Transmitted Infections.Journal of clinical laboratory analysis · 2025Review
- Antimicrobial Peptides: A Promising Solution to the Rising Threat of Antibiotic Resistance.Pharmaceutics · 2024Review
- Antimicrobial peptides: A novel and promising arsenal against methicillin-resistantPharmaceutical science advances · 2024Review
- Article
- Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses.International journal of molecular sciences · 2023Article
- Glycosylation and Lipidation Strategies: Approaches for Improving Antimicrobial Peptide Efficacy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Molecular Research on Oral Diseases and Related Biomaterials: A Journey from Oral Cell Models to Advanced Regenerative Perspectives.International journal of molecular sciences · 2022Review
- WMR Peptide as Antifungal and Antibiofilm against Albicans and Non-Albicans Candida Species: Shreds of Evidence on the Mechanism of Action.International journal of molecular sciences · 2022Article
- Article
- Antimicrobial peptides: mechanism of action, activity and clinical potential.Military Medical Research · 2021Review
- Tick defensin γ-core reduces Fusarium graminearum growth and abrogates mycotoxins production with high efficiency.Scientific reports · 2021Article
- Molecular engineering of antimicrobial peptides: microbial targets, peptide motifs and translation opportunities.Biophysical reviews · 2021Review
- Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination.International journal of environmental research and public health · 2021Review
- Peptides and Dendrimers: How to Combat Viral and Bacterial Infections.Pharmaceutics · 2021Review
- HNP-1 and HBD-1 as Biomarkers for the Immune Systems of Elite Basketball Athletes.Antibiotics (Basel, Switzerland) · 2020Article
- Human Defensins: A Novel Approach in the Fight against Skin ColonizingAntibiotics (Basel, Switzerland) · 2020Review
- Porcine β-defensin 2 inhibits proliferation of pseudorabies virus in vitro and in transgenic mice.Virology journal · 2020Article
- Strategies in Translating the Therapeutic Potentials of Host Defense Peptides.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have designed a cyclic 17-amino acid β-defensin analog featuring a single disulfide bond. This analog, designated "AMC" (ie, antimicrobial cyclic peptide), combines the internal hydrophobic domain of hBD1 and the C-terminal charged region of hBD3. The novel peptide was synthesized and characterized by nuclear magnetic resonance spectroscopy. The antimicrobial activities against gram-positive and gram-negative bacteria as well as against herpes simplex virus type 1 were analyzed. The cytotoxicity and serum stability were assessed. Nuclear magnetic resonance of AMC in aqueous solution suggests that the structure of the hBD1 region, although not identical, is preserved. Like the parent defensins, AMC is not cytotoxic for CaCo-2 cells. Interestingly, AMC retains the antibacterial activity of the parent hBD1 and hBD3 against Pseudomonas aeruginosa, Enterococcus faecalis, and Escherichia coli, and exerts dose-dependent activity against herpes simplex virus type 1. Moreover, while the antibacterial and antiviral activities of the oxidized and reduced forms of the parent defensins are similar, those of AMC are significantly different, and oxidized AMC is also considerably more stable in human serum. Taken together, our data also suggest that this novel peptide may be added to the arsenal of tools available to combat antibiotic-resistant infectious diseases, particularly because of its potential for encapsulation in a nanomedicine vector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.